ANTG produce exclusive high-quality cannabinoid based medicinal treatments that can meet individual patient needs. We combine a strong research focus with best in class cultivation and extraction methods to develop cannabinoid medicines that offer safe and effective therapeutic benefits to patients.
Our team has witnessed first-hand the power of medicinal cannabis in relieving chronic and debilitating disease symptoms in areas where traditional treatments lack efficacy and or have significant side effects. It’s these personal experiences that motivated us to establish our company in 2015.
Our passion for the plant underpins our focus on putting the needs of patients first – and we believe, as an independent company, that we are uniquely positioned to achieve more and be more for the benefit of humanity.
Our team is motivated by the possibilities and health benefits that medicinal cannabis offers.
Led by a board of skilled commercial leaders our team also includes experienced horticulturists, scientific researchers and medical advisors.
Matt leads the ANTG team. A former director and COO of one of the world’s leading travel management companies, Matt helped guide the business to IPO in 2010. Since then Matt has been investing in and advising various successful ventures across a number of sectors including technology, security, social media, nutrition and fitness, and real estate.
James oversees the ongoing business operations and corporate development of ANTG. With an executive leadership background in the travel, technology and advertising industries, James has led brands, projects and operational initiatives globally in travel, IT, automotive, CPG, finance, beauty and manufacturing. James also serves as an investor and board advisor to a number of businesses in security technology, travel distribution, talent management and recruitment.
Rangi worked in aquaculture for over a decade until 2015 when he followed his calling to help create a medical cannabis industry in Australia. Rangi then obtained a hemp research license, a cultivation facility, and began to selectively breed for specific cannabinoid profiles suitable for therapeutic use. Rangi has tested several hundred plants using high pressure liquid chromatography (HPLC). He is also trained and experienced in the operation of super critical Co2 resin extraction equipment.
Jarrad brings a strong background in property and construction underpinned by extensive experience in horticulture, e-commerce and logistics. Jarrad has developed numerous industry contacts in the medicinal cannabis markets of USA, Canada, Holland and Australia. He has also built experience in horticulture and learnt best-practice techniques pertaining to the medical cannabis industry.
Dr Teresa Nicoletti is a Partner in the Intellectual Property, Health and Life Sciences team at Mills Oakley. She is both a lawyer and a scientist with 25 years’ experience in the pharmaceutical, biotechnology and medical device industries in Australia and New Zealand and has also worked across a number of other product-related industries, including food, cosmetics, veterinary pharmaceuticals, agrochemicals and industrial chemicals. Teresa is regarded as Australia’s leading expert in medicinal cannabis law and was the Lawyers Weekly Partner of the Year in Health in 2017 and 2016. She is also ranked as a Band 1 lawyer in the Life Sciences category in Chambers Asia Pacific 2018.
A collaboration of leaders in the government-sanctioned cannabis industry. With representation from government, private-sector and affiliate organizations, the Partnership promotes the safe and responsible production, distribution and consumption of legal cannabis.
A pharmaceutical consulting company offering leading GMP compliance, validation, regulatory, engineering and architectural consulting services solutions to the pharmaceutical and life science industries.
Seed-to-sale management software that provides tools and analytics to optimize operations.
Australia’s peak national industry association representing cultivators, manufacturers, distributors, ancillary organisations, education and advocacy groups, researchers and more.
DRIVEN BY EXCELLENCE. DEFINED BY QUALITY.
From tiny seeds to refined medicines, ANTG is committed to quality control at every step of the cultivation, extraction and production process. Our Australian facilities use world-leading processes to ensure optimal quality and medicinal benefit. This includes chemical-free CO2 extraction, high-performance liquid and gas chromatography, mass spectrometry, cutting-edge distillation tools and complete traceability through the end-to-end production process.
Chris Wright, Brisbane local who was diagnosed with Tourette’s syndrome at the age of 12 is one of the first patients recruited for the trial run by Brisbane’s Wesley Medical Research. The trial aims to assess the effects of medicinal cannabis on symptoms such as uncontrollable physical and/or verbal ticks.
ANTG becomes first Australian member of The Global Cannabis Partnership (GCP), not-for-profit collaboration of leaders in the government-sanctioned cannabis industry. The partnership offers a great opportunity for the company to take part in shaping the future of medicinal cannabis industry.
Our CEO and founder, Matt Cantelo has recently met with the editor of the local newspaper, The Northern Daily Leader to discuss ANTG’s partnership with Cannamedical Pharma, German pharmaceutical company and its plans for growth, including the opening of their new facility in Armidale.
We ensure that all of our processes are environmentally friendly, and have procedures to ensure compliance with our carbon footprint policy. Our facilities are equipped with green water systems and specialised waste treatment procedures. At ANTG, we assume responsibility for the community at large and not just our customers. We only use ethically responsible products – no compromise.